Introduction
Radiation therapy (RT) is a longstanding pillar of cancer treatment, historically utilized to treat a discrete target and provide local tumor control. Mounting evidence demonstrates that RT also elicits an immune response that can manifest as an immune-mediated tumor regression outside of the targeted site [1]. The potential ability of RT to induce an immunogenic cell death and counteract an immune-suppressive tumor microenvironment to effectively convert the irradiated tumor into an in situ vaccine has implications for both local and systemic disease control, and provides the primary rationale for combining novel immunotherapies with RT.
The combination of immunotherapy with RT is an actively growing field of clinical investigation, with rapid expansion in the number and type of clinical trials. After a brief summary on the immunomodulatory properties of radiation, this review will describe some of the available types of immunotherapies that are currently being tested in combination with radiotherapy. We will discuss the challenges in the design and evaluation of current trials, including selection of appropriate radiation dose, fractionation, sequencing of therapies and meaningful trial endpoints.
Advertisement
Radiation and immune-mediated tumor response
Historically, RT has been considered to be immunosuppressive, based on older treatment techniques with large fields that included substantial bone marrow volume and/or circulating blood volume resulting in reduced blood cell counts [2, 3]. In addition, because of the relative radio-sensitivity of hematopoietic cells, whole-body RT regimens are used prior to stem cell transplantation to cause lympho- and myelo-ablation [4, 5].
To minimize side effects to normal tissue, conventional treatment regimens deliver the radiation dose that is effective at controlling a tumor (40 to 70 Gy, depending on tumor type) in multiple small daily doses, given over several weeks. Advancements in RT equipment and planning systems allow delivery of highly conformal treatment with increased precision, and as a result, it is now possible to deliver higher doses per fraction while sparing adjacent normal tissue. Techniques such as stereotactic radiosurgery and body radiation therapy (SRS, SBRT), intensity modulated radiation therapy (IMRT) and image-guided radiation therapy (IGRT) have transformed delivery of RT, broadening the range of RT applications. Since the effects of radiation on the immune system and on the tumor microenvironment may depend on the dose and delivery methods used, when radiation is used to stimulate an anti-tumor immune response in combination with immunotherapy thoughtful considerations on delivery techniques, dose, and fractionation are warranted.
The traditional model of radiation-induced tumor control that forms the basis for conventional fractionated RT regimens is built on four well-established principles of radiobiology, the fours “Rs”: reassortment of cells to a cell cycle phase that is radiation-sensitive after each fraction; repair of sublethal damage in normal cells to decrease toxicity, reoxygenation of hypoxic tumor regions, and repopulation [6]. In this model, the therapeutic effect of radiation is mainly attributed to direct DNA damage and indirect damage from free radical formation [7]. However, preclinical studies over the past decade have demonstrated an important contribution from the effects of RT on the tumor microenvironment and on the anti-tumor immune response, giving rise to the concept that the fifth “R” of radiobiology is immune-mediated tumor Rejection [8].
The multitude of biological responses elicited by RT that have been shown in experimental models to convert the irradiated tumor into an in situ vaccine have been detailed in several recent reviews [9‐11]. Here, we will only briefly highlight a few concepts that more significantly impact clinical trial design. In vitro, immunogenic cell death (ICD) is induced by RT in a dose-dependent way [12], suggesting that larger doses should have more pro-immunogenic effects. However, in vivo data suggest a more complex relationship with dose and fractionation. The ability of RT to induce priming of anti-tumor T cells is influenced by the pre-existing tumor microenvironment, and by the effects of RT on immune cells and other components of the tumor microenvironment [7]. So far, pre-clinical studies have not achieved a consensus about the optimal dose and regimen to be used to stimulate the immune system, with some studies supporting the use a single large doses (e.g., 30 Gy), and others showing that standard dose of 2 Gy or classical hypo-fractionated doses of 6 or 8 Gy delivered daily in consecutive days are more effective [13‐15]. Importantly, radiation-induced T cell responses to immunogenic exogenous antigens (e.g., ovalbumin) expressed by tumors at relatively high levels were demonstrated [16]. However, in other experiments induction of T cell responses to shared tumor antigens derived from self-proteins that are over-expressed by cancer cells could not be detected unless mice were given immunotherapy to overcome key immunosuppressive pathways [10]. Thus, while several types of immunotherapy have been shown to work in concert with RT to induce anti-tumor T cell responses, [9] the requirements for a specific combination to be effective, in terms of RT dose and fractionation and sequencing of RT with immunotherapy have not been fully explored in pre-clinical studies, leaving multiple open questions for optimal design of a clinical study.
Advertisement
In the next paragraphs, we will succinctly describe the available immunotherapies, then focus on active clinical trials that are investigating their synergy with radiation.
Immunotherapy: new therapeutic opportunities
Significant progress in immuno-oncology has led to new treatments such as immune checkpoint blockade, adoptive T cell transfer, cytokine therapy, dendritic cell and peptide vaccines, and monoclonal antibody treatment. Many of these immunotherapies have been tested in combination with RT in pre-clinical studies and are under investigation in the clinic.
Induction of anti-tumor immunity is a multi-step process, which is regulated at every step by positive and negative signals [17]. First, tumor antigens must reach professional antigen-presenting cells (APCs), such as dendritic cells, which upon activation migrate to draining lymph nodes. There, DCs, after processing the peptides in the proteasome, present them as part of the major histocompatibility (MHC) molecules to T cells, in the context of co-stimulatory signals that result in T cell activation and proliferation. Once activated, tumor-specific T cells differentiate into effectors and home to the tumor where they must overcome the existing immune-suppressive microenvironment to successfully reject it. Other T cells differentiate into memory T cells, potentially capable to protect the host from micrometastatic disease that emerges from dormancy and prevent tumor recurrence [18]. Immunotherapies currently approved and in development act at one or more of the steps of this process. RT has been shown to potentially enhance each step, including uptake of tumor antigens by dendritic cells and their activation, as well as migration of the activated effector T cells back to the tumor. Thus RT could enhance and complement the action of many different immunotherapy agents [19‐21].
Some of the emerging therapies are summarized below, along with combination approaches incorporating RT.
Immune checkpoint blockade
Immune checkpoints trigger downstream signaling pathways that inhibit T cells activation and/or effector function and maintain a balance between stimulation and suppression of immune function, thereby preventing autoimmunity. Antibodies against two immune checkpoints have been approved by FDA for treatment of some cancers.
Cytotoxic T-lymphocyte antigen 4 (CTLA-4)
CTLA-4 is an inhibitory receptor that is upregulated after T-cell activation, and transmits signals that suppress T-cell activation and proliferation [22]. It is also expressed at high levels on tumor-infiltrating regulatory T cells (Tregs) and antibodies targeting CTLA-4 can selectively deplete these cells by antibody-mediated cellular cytotoxicity (ADCC) mechanisms [23].
One antibody targeting CTLA-4, ipilimumab (Yervoy, Bristol Myers Squibb), is approved for metastatic melanoma [24]. Tremelimumab is another anti-CTLA-4 antibody currently under development by MedImmune/Astra Zeneca.
A seminal preclinical study demonstrated that RT is synergistic with anti-CTLA antibody and induces systemic anti-tumor responses in a poorly immunogenic carcinoma refractory to anti-CTLA-4 monotherapy [25]. Since that time, there have been multiple case reports and retrospective series reporting abscopal effects in patients receiving RT during treatment with ipilimumab [26‐29].
Dose and fractionation schedule likely play an important role in response. Preclinical models support use of hypofractionated RT in daily doses of 6 to 8 Gy given 5 or 3 times, over a single high dose treatment of 20 Gy, in order to maximize likelihood of generating an effective anti-tumor immune response with anti-CTLA-4 [15]. Consistent with this finding, the most dramatic cases of abscopal effect reported with ipilimumab and RT have utilized RT doses and fractionation [26, 27, 29, 30] similar to the RT regimens effective in preclinical studies. However, abscopal effects were also reported in patients treated with a wider range of RT doses [26, 29, 31].
While most abscopal responses reported with addition of RT to ipilimumab were in melanoma, a disease responsive to ipilimumab alone, a notable exception was a patient with metastatic non-small cell lung cancer (NSCLC) resistant to multiple lines of systemic chemotherapy who was treated with ipilimumab and 5 fractions of 6 Gy RT to a single liver metastasis [30]. This resulted in a complete and durable response. A phase 2 study evaluating this regimen (NCT02221739) in NSCLC completed enrollment and confirmed the activity of RT + ipilimumab in a disease that was non-responsive to anti-CTLA-4 alone [32].
A phase 1 dose escalation trial (NCT01497808) evaluated 22 patients with metastatic melanoma, treated with 2-3 fractions of RT to a single lung or osseous metastasis, or 6 Gy to a subcutaneous or hepatic metastasis, followed by ipilimumab [33]. There were no complete responses, though partial responses were noted in 18 % of unirradiated lesions. However, given that ipilimumab at baseline has activity in metastatic melanoma, it is uncertain the degree to which RT contributed to tumor regression.
A phase 1/2 trial enrolled men with metastatic castrate-resistant prostate cancer, and escalated the dose of ipilimumab, with or without concurrent single fraction RT (8 Gy) targeting an osseous metastasis [34]. This approach was further evaluated in a subsequent, multi-institutional, phase 3 trial (NCT00861614) with 799 patients diagnosed with metastatic castrate-resistant prostate cancer, treated with 1 fraction (8 Gy) RT to an osseous metastasis and randomized to ipilimumab or placebo [35]. Primary endpoint of improved overall survival was not achieved, though P-value was close to the cut off for significance (P = 0.0530). On subset analysis, patients with non-visceral metastatic disease treated with ipilimumab combined with RT experienced an incremental improvement in overall survival, suggesting non-visceral metastases may be a more appropriate target for RT in combination with ipilimumab. Furthermore, this study demonstrated that the combination of RT and ipilimumab was overall well-tolerated with minimal added toxicity.
Currently ongoing trials combining CTLA-4 inhibition with RT are summarized in Table 1. Metastatic melanoma is the most common primary diagnosis under study, and majority of studies are evaluating RT and CTLA-4 blockade administered in concurrent fashion.
Table 1
Active clinical trials combining radiation with CTLA-4 inhibition
NCT Number | Phase | Title | Conditions | Interventions | RT Details | Enrollment | Sponsor/Collaborators |
|---|---|---|---|---|---|---|---|
NCT01711515 | Phase 1 | Chemoradiation Therapy and Ipilimumab in Treating Patients With Locally Advanced Cervical Cancer | Cervical Cancer | Cisplatin, Ipilimumab | EBRT 6 weeks | 28 | National Cancer Institute (NCI) |
NCT02406183 | Phase 1 | Trial of SBRT With Concurrent Ipilimumab in Metastatic Melanoma | Melanoma | Ipilimumab | SBRT 8-12 Gy × 3 fx | 21 | Radiotherapie|University Hospital, Ghent |
NCT01935921 | Phase 1 | Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer | Stage III-IVB Head and Neck Cancer | Cetuximab, Ipilimumab | IMRT, 7 wks | 18 | National Cancer Institute (NCI) |
NCT02659540 | Phase 1 | A Pilot Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma | Melanoma | Ipilimumab, Nivolumab | EBRT 3 Gy × 10 fx or 9 Gy × 3 fx | 18 | Ludwig Institute for Cancer Research|Bristol-Myers Squibb |
NCT01860430 | Phase 1 | A Phase Ib Trial of Concurrent Cetuximab (ERBITUX) and Intensity Modulated Radiotherapy (IMRT) With Ipilimumab (YERVOY) in Locally Advanced Head and Neck Cancer | Head and Neck Cancer | Ipilimumab, Cetuximab | IMRT, 7 wks | 18 | University of Pittsburgh|National Cancer Institute (NCI) |
NCT01996202 | Phase 1 | A Pilot Study of Ipilumimab and Radiation in Poor Prognosis Melanoma | Melanoma | Ipilimumab | EBRT | 24 | Duke University |
NCT02311361 | Phase 1 | Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer | Pancreatic Cancer | Tremelimumab, MEDI4736 | SBRT, 1-5 fx | 60 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
NCT02239900 | Phase 1|Phase 2 | Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors | Liver cancer, Lung Cancer | Ipilimumab | SBRT 12.5 Gy × 4 fx | 120 | M.D. Anderson Cancer Center|Bristol-Myers Squibb |
NCT02696993 | Phase 1|Phase 2 | Phase I/II Trial of Nivolumab With Radiation or Nivolumab and Ipilimumab With Radiation for the Treatment of Intracranial Metastases From Non-Small Cell Lung Cancer | Brain Metastases (NSCLC) | Nivolumab, Ipilimumab | WBRT 3 Gy × 10 fx, SRS 1 fxa
| 80 | M.D. Anderson Cancer Center|Bristol-Myers Squibb |
NCT02254772 | Phase 1|Phase 2 | TLR9 Agonist SD-101, Ipilimumab, and Radiation Therapy in Treating Patients With Low-Grade Recurrent B-cell Lymphoma | B-cell Lymphoma | Ipilimumab, TLR9 agonist SD-101 | RT days 1, 2 | 27 | Ronald Levy|National Cancer Institute (NCI)|Stanford University |
NCT01565837 | Phase 2 | SART: Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma | Melanoma | Ipilimumab | SBRT 1-5 fx | 50 | Wolfram Samlowski|Comprehensive Cancer Centers of Nevada |
NCT01970527 | Phase 2 | Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma | Recurrent/Stage IV Melanoma | Ipilimumab | SBRT 3 fx | 40 | |
NCT02107755 | Phase 2 | Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma | Melanoma | Ipilimumab | SBRT | 32 | Ohio State University Comprehensive Cancer Center|Bristol-Myers Squibb |
NCT02097732 | Phase 2 | Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery | Brain Metastases (Melanoma) | Ipilimumab | SRS 1 fxa
| 40 | University of Michigan Cancer Center |
NCT02115139 | Phase 2 | GRAY-B: GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases | Melanoma | Ipilimumab | WBRT 3 Gy × 10 fx | 66 | Grupo Espanol Multidisciplinar de Melanoma|Bristol-Myers Squibb |
NCT02701400 | Phase 2 | Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Tremelimumab, Durvalumab | SBRT | 20 | Emory University|AstraZeneca |
NCT02434081 | Phase 2 | NICOLAS: NIvolumab COnsolidation After Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B NSCLC | NSCLC | Nivolumab | EBRT | 43 | European Thoracic Oncology Platform|Bristol-Myers Squibb|Frontier Science Foundation, Hellas |
NCT01449279 | Pilot | Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy | Stage IV Melanoma | Ipilimumab | Palliative RT | 20 | Stanford University |
Programmed death-1 (PD-1)/Programmed death ligand -1(PD-L1)
PD-1 is an inhibitory cell surface receptor that acts as an immune checkpoint. Its ligand, PD-L1 is expressed on diverse types of cells, including antigen-presenting cells, epithelial and endothelial cells. Studies have shown that PD-1 and PD-L1 targeted therapies have clinical activity against metastatic bladder cancer, head and neck cancers, Hodgkin’s lymphoma, non-small cell lung cancer, and renal cell cancer [36]. Anti-PD-1 therapies, pembrolizumab (MK-3475/Keytruda, Merck & Co) and nivolumab (Opdivo, Bristol-Meyers Squibb Co), are currently approved as treatment for unresectable or metastatic melanoma, and as second-line treatment for non-small cell lung cancer (NSCLC) after chemotherapy. Nivolumab has been recently approved for Hodgkin’s lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation, and metastatic renal cell carcinoma. Atezolizumab (MPDL3280A) and durvalumab (MEDI-4736) are monoclonal anti PD-L1 antibodies currently under active investigation in clinical trials. Atezolizumab has been recently approved by FDA for locally advanced or metastatic urothelial carcinoma progressing during or after platinum chemotherapy. REGN2810 is a monoclonal antibody that binds to PD-1 and inhibits PD-L1 mediated activation of downstream pathways.
Preclinical studies demonstrate that the combination of RT and targeted PD-1/PD-L1 therapy activates cytotoxic T-cells, reduces myeloid-derived suppressor cells and induces an abscopal response [14, 37, 38]. Based on these promising results, numerous ongoing clinical trials are testing the combination of PD-1/PD-L1 inhibition and RT (Table 2). Majority of studies are phase 1 or 2. There are two open phase 3 trials looking at combination of nivolumab with RT in locally advanced NSCLC (NCT02768558), and glioblastoma (NCT02617589), respectively; results are pending.
Table 2
Active clinical trials combining radiation with PD-1/PD-L1 targeted therapy
NCT Number | Phase | Title | Conditions | RT Details | Enrollment | Sponsor/Collaborators |
|---|---|---|---|---|---|---|
NCT02642809 | Phase 0 | Pembrolizumab With Locally Delivered Radiation Therapy for the Initial Treatment of Metastatic Esophageal Cancers | Esophageal Cancer | Hypofx brachytherapy | 15 | Washington University School of Medicine|Merck Sharp & Dohme Corp. |
NCT02463994 | Phase 0 | A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC | NSCLC | Hypofx RT | 12 | University of Michigan Cancer Center|University of Washington |
NCT02587455 | Phase 1 | Pembrolizumab and Palliative Radiotherapy in Lung | Thoracic Tumours | Palliative EBRT | 48 | Royal Marsden NHS Foundation Trust|Merck Sharp & Dohme Corp. |
NCT02608385 | Phase 1 | Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors | NSCLC | SBRT, 3-5 fx | 138 | University of Chicago |
NCT02621398 | Phase 1 | Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB NSCLC | NSCLC | EBRT | 30 | Rutgers, The State University of New Jersey|National Cancer Institute (NCI)|Merck Sharp & Dohme Corp. |
NCT02313272 | Phase 1 | Phase I Trial of Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas | Malignant Glioma | FSRT over 5 days | 32 | H. Lee Moffitt Cancer Center and Research Institute|Merck Sharp & Dohme Corp. |
NCT02402920 | Phase 1 | Phase I Trial of MK-3475 and Concurrent Chemo/Radiation for the Elimination of Small Cell Lung Cancer | Lung Cancer | EBRT, 1.5 Gy × 30 fx, BID | 80 | M.D. Anderson Cancer Center|Merck Sharp & Dohme Corp. |
NCT02716948 | Phase 1 | Stereotactic Radiosurgery and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine | Melanoma (Brain metastases) | SRS | 90 | Sidney Kimmel Comprehensive Cancer Center |
NCT02560636 | Phase 1 | Pembrolizumab in Muscle Invasive/Metastatic Bladder Cancer | Invasive Bladder Cancer | Hypofx RT | 34 | Royal Marsden NHS Foundation Trust|Merck Sharp & Dohme Corp. |
NCT02318771 | Phase 1 | Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer | Metastatic HN, RCC, Melanoma, Lung Cancer | EBRT | 40 | Thomas Jefferson University|Merck Sharp & Dohme Corp. |
NCT02648633 | Phase 1 | Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma | Glioblastoma | SRS | 17 | University of Virginia |
NCT02303366 | Phase 1 | Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475 | Oligometastatic Breast Cancer | SBRT, 20 Gy × 1 fx | 15 | Peter MacCallum Cancer Centre, Australia |
NCT02659540 | Phase 1 | A Pilot Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma | Melanoma | 3 Gy × 10 fx, or 9 Gy × 3 fx | 18 | Ludwig Institute for Cancer Research|Bristol-Myers Squibb |
NCT02586207 | Phase 1 | Pembrolizumab in Combination With CRT for LA-SCCHN | Advanced HN Cancers | EBRT, 7 wks | 39 | Sanford Health|Merck Sharp & Dohme Corp. |
NCT02303990 | Phase 1 | RADVAX: A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers | Metastatic Cancers | Hypofx RT | 70 | Abramson Cancer Center of the University of Pennsylvania |
NCT02764593 | Phase 1 | Chemotherapy +/- Nivolumab in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma | Advanced HN Cancers | IMRT, 7 wks | 120 | RTOG Foundation, Inc.|Bristol-Myers Squibb |
NCT02400814 | Phase 1 | MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With NSCLC | NSCLC | SBRT, 5 fx | 45 | University of California, Davis|National Cancer Institute (NCI)|Genentech, Inc. |
NCT02383212 | Phase 1 | Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies | Advanced Cancer | Hypofx RT | 973 | Regeneron Pharmaceuticals|Sanofi |
NCT02311361 | Phase 1 | Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer | Pancreatic Cancer | SBRT, 1-5 fx | 60 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
NCT02696993 | Phase 1|Phase 2 | Phase I/II Trial of Nivolumab With Radiation or Nivolumab and Ipilimumab With Radiation for the Treatment of Intracranial Metastases From NSCLC | Lung Cancer (Brain metastases) | WBRT 3 Gy × 10 fx, SRS 1 fx | 80 | M.D. Anderson Cancer Center|Bristol-Myers Squibb |
NCT02444741 | Phase 1|Phase 2 | MK-3475 and Hypofractionated Stereotactic Radiation Therapy in Patients With NSCLC (NSCLC) | Lung Cancer | EBRT or SBRT | 104 | M.D. Anderson Cancer Center|Merck Sharp & Dohme Corp. |
NCT02530502 | Phase 1|Phase 2 | Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma | Glioblastoma | EBRT | 50 | Northwestern University|Merck Sharp & Dohme Corp.|National Cancer Institute (NCI) |
NCT02730546 | Phase 1|Phase 2 | Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery | Gastric Cancer | EBRT | 68 | Mayo Clinic|National Cancer Institute (NCI) |
NCT02759575 | Phase 1|Phase 2 | A Study of Chemoradiation Plus Pembrolizumab for Locally Advanced Laryngeal Squamous Cell Carcinoma | Advanced HN Cancers | EBRT | 47 | Nooshin Hashemi-Sadraei|Merck Sharp & Dohme Corp.|University of Cincinnati |
NCT02407171 | Phase 1|Phase 2 | Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC | Melanoma, Lung Cancer | SBRT, 1-5 fx | 60 | Yale University |
NCT02735239 | Phase 1|Phase 2 | Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer | Esophageal Cancer | EBRT | 75 | Ludwig Institute for Cancer Research|AstraZeneca |
NCT02305186 | Phase 1|Phase 2 | Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer | Pancreatic Cancer | EBRT, 1.8 Gy × 28 fx | 56 | Osama Rahma, MD|M.D. Anderson Cancer Center|University of Virginia |
NCT02599779 | Phase 2 | A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients | Metastatic RCC | SBRT | 35 | Sunnybrook Health Sciences Centre|Merck Sharp & Dohme Corp.|Ozmosis Research Inc. |
NCT02648282 | Phase 2 | Study With CY, Pembrolizumab, GVAX, and SBRT in Patients With Locally Advanced Pancreatic Cancer | Pancreatic Cancer | SBRT, 3-5 fx | 54 | Sidney Kimmel Comprehensive Cancer Center|Merck Sharp & Dohme Corp. |
NCT02492568 | Phase 2 | Pembrolizumab After SBRT Versus Pembrolizumab Alone in Advanced NSCLC | NSCLC | SBRT, 8 Gy × 3 fx | 74 | The Netherlands Cancer Institute|Merck Sharp & Dohme Corp. |
NCT02641093 | Phase 2 | Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma | HN Cancer | EBRT, 6 wks | 80 | Trisha Wise-Draper|Merck Sharp & Dohme Corp.|University of Cincinnati |
NCT02684253 | Phase 2 | Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) | HN Cancer | SBRT, 9 Gy x 3 fx | 40 | Memorial Sloan Kettering Cancer Center|University of Chicago |
NCT02667587 | Phase 2 | Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer). | Glioblastoma | EBRT | 320 | Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd |
NCT02437071 | Phase 2 | Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer Patients | Metastatic Colorectal Cancer | EBRT vs radiofrequency ablation | 48 | Memorial Sloan Kettering Cancer Center|Merck Sharp & Dohme Corp. |
NCT02658097 | Phase 2 | A Randomized Two Arm Phase II Trial of Pembrolizumab Alone or Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC | Stage IV NSCLC | 8 Gy × 1 fx | 66 | Case Comprehensive Cancer Center |
NCT02562625 | Phase 2 | Trial of Pembrolizumab and Radiotherapy in Melanoma | Melanoma | 8 Gy × 3 fx | 234 | Royal Marsden NHS Foundation Trust|University of Manchester|University of Leeds |
NCT02730130 | Phase 2 | Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients | Metastatic Breast Cancer | EBRT | 17 | Memorial Sloan Kettering Cancer Center|Merck Sharp & Dohme Corp. |
NCT02707588 | Phase 2 | Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With RT in Patients With Locally Advanced HNSCC | Advanced HN Cancers | EBRT | 114 | Groupe Oncologie Radiotherapie Tete et Cou |
NCT02621151 | Phase 2 | Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder | Muscle-invasive Urothelial Cancer of the Bladder | Hypofx RT | 54 | New York University School of Medicine|Merck Sharp & Dohme Corp. |
NCT02609503 | Phase 2 | Pembrolizumab + Radiation for Locally Adv SCC of the Head and Neck (SCCHN) Not Eligible Cisplatin | Head and Neck Cancer | IMRT, 7 wks | 29 | UNC Lineberger Comprehensive Cancer Center|Merck Sharp & Dohme Corp. |
NCT02677155 | Phase 2 | Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular Lymphoma | Follicular Lymphoma | 8 Gy × 1 fx | 20 | Oslo University Hospital|Norwegian Cancer Society|Merck Sharp & Dohme Corp. |
NCT02586610 | Phase 2 | Trial of Chemoradiation and Pembrolizumab in Patients With Rectal Cancer | Rectal Cancer | EBRT, 1.8 Gy × 28 fx | 53 | Osama Rahma, MD|Hoosier Cancer Research Network|Merck Sharp & Dohme Corp. |
NCT02434081 | Phase 2 | NIvolumab COnsolidation After Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B NSCLC | NSCLC | EBRT | 43 | European Thoracic Oncology Platform|Bristol-Myers Squibb|Frontier Science Foundation, Hellas |
NCT02296684 | Phase 2 | Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma | HN Cancer | IMRT, 6 wks | 46 | Washington University School of Medicine|Merck Sharp & Dohme Corp. |
NCT02499367 | Phase 2 | Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) Patients | Breast Cancer | 20 Gy × 1, or 8 Gy × 3 | 84 | The Netherlands Cancer Institute|Bristol-Myers Squibb |
NCT02635360 | Phase 2 | Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer | Cervical Cancer | EBRT + brachytherapy | 88 | Linda R Duska|Merck Sharp & Dohme Corp.|University of Virginia |
NCT02662062 | Phase 2 | Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer | Bladder Cancer | EBRT, 6 wks | 30 | Australian and New Zealand Urogenital and Prostate Cancer Trials Group |
NCT02336165 | Phase 2 | Phase 2 Study of MEDI4736 in Patients With Glioblastoma | Glioblastoma | EBRT | 108 | Ludwig Institute for Cancer Research|MedImmune LLC |
NCT02289209 | Phase 2 | Reirradiation With MK-3475 (Pembrolizumab) in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck | Recurrent HN Cancers | EBRT | 48 | Dan Zandberg|Merck Sharp & Dohme Corp.|University of Maryland |
NCT02768558 | Phase 3 | Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC | NSCLC | EBRT (IMRT or 3D CRT) | 660 | RTOG Foundation, Inc.|Bristol-Myers Squibb |
NCT02617589 | Phase 3 | Study of Nivolumab Versus Temozolomide, Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) | Brain Cancer | EBRT | 550 | Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd |
Transforming growth factor beta (TGFβ) targeting
TGFβ is a cytokine with immunosuppressive activity that is activated by RT in the tumor microenvironment [39‐41]. Preclinical studies have shown that inhibition of TGFb during and after RT allows priming of T cells to multiple tumor antigens leading to immune-mediated regression of the irradiated tumor and non-irradiated metastases [41]. A few clinical studies are ongoing to test the benefits of TGFβ inhibition and RT (Table 3). One phase 1/2 trial in patients with metastatic breast tested the use of a neutralizing antibody, fresolimumab, with RT and is closed to accrual (NCT01401062). A second trial in the same patient population is accruing and uses a small molecule inhibitor, LY2157299, to target the TGFb receptor (NCT02538471). Fresolimumab is also being tested in the SABR-ATAC phase 1/2 trial in patients with stage IA/IB non-small cell lung cancer with the primary endpoint of evaluating late RT-induced fibrosis inhibition in the phase 2 study (NCT02581787). Another phase 2 study testing LY2157299 in rectal cancer in combination with chemotherapy and RT is not yet open (NCT02688712). A phase 1b/2a study in testing chemoRT and LY2157299 in glioma patients has completed accrual (NCT01220271).
Table 3
Active clinical trials combining radiation with TGF-β blockade or GM-CSF
NCT Number | Phases | Title | Condition | Intervention | RT Details | Enrollment | Sponsor/Collaborators |
|---|---|---|---|---|---|---|---|
Anti-TGF- β | |||||||
NCT02538471 | Phase 2 | LY2157299 Monohydrate (LY2157299) and Radiotherapy in Metastatic Breast Cancer | Metastatic Breast Cancer | LY2157299 | RT, 7.5 Gy × 3 fx | 28 | Weill Medical College of Cornell University|University of California, Los Angeles |
NCT02581787 | Phase 1|Phase 2 | SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer | Stage IA-B NSCLC | Fresolimumab | SBRT, 4 fx | 60 | Maximilian Diehn|National Cancer Institute (NCI)|Stanford University |
GM-CSF | |||||||
NCT02623595 | Phase 2 | A Study of SBRT in Combination With rhGM-CSF for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy | Non-small cell lung cancer | GM-CSF | SBRT, 10 Gy × 5 fx | 60 | Wuhan University|Tongji Hospital|Hubei Cancer Hospital |
NCT02663440 | Phase 2 | Trial of Hypofractionated Intensity Modulated Radiation Therapy With Temozolomide and Granulocyte-macrophage Colony-stimulating Factor for Patients With Newly Diagnosed Glioblastoma Multiforme | Glioblastoma | GM-CSF, Temozolomide | Hypofx IMRT | 41 | Zhejiang Cancer Hospital |
NCT02677155 | Phase 2 | Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular Lymphoma | Follicular Lymphoma | GM-CSF, Pembrolizumab, Rituximab, autologous dendritic cells | 8 Gy × 1 | 20 | Oslo University Hospital|Norwegian Cancer Society|Merck Sharp & Dohme Corp. |
NCT02648282 | Phase 2 | Study With CY, Pembrolizumab, GVAX, and SBRT in Patients With Locally Advanced Pancreatic Cancer | Pancreatic Cancer | GVAX, Cyclophosphamide, Pembrolizumab | SBRT, 6.6 Gy × 5 fx | 54 | Sidney Kimmel Comprehensive Cancer Center|Merck Sharp & Dohme Corp. |
Cytokines
Granulocyte macrophage colony-stimulating factor (GM-CSF)
GM-CSF is a growth factor secreted by macrophages, T-cells, NK cells, endothelial cells and fibroblasts, promoting maturation of dendritic cells and enabling cross-presentation of tumor cell antigens to generate memory T-cells. Preclinical data supports the combination of RT and cytokines to generate an abscopal effect [42]. Based on this, a proof-of-principle pilot study was initiated with 10 fractions of RT (3.5 Gy per fraction) directed to a metastatic lesion and 14 days of GM-CSF. Out of 41 patients with varied tumor histologies, 11 (26.8 %) exhibited clinical response outside of the RT field [43].
GM-CSF gene-transduced tumor cells have shown promise as vaccines (GVAX), demonstrating durable tumor regression in clinical trials enrolling patients with advanced NSCLC, and reports of tumor regression in patients with renal cell carcinoma and melanoma [44]. Currently ongoing trials utilizing GM-CSF or GVAX with radiation are summarized in Table 3. There are far fewer studies for GM-CSF in combination with RT in comparison to immune check point inhibitors.
Interleukin-2 (IL-2)
IL-2 is a cytokine produced by T-cells that stimulates T-cell proliferation and antigen-specific differentiation. Treatment with high-dose IL-2 has been documented to induce a complete response in patients with metastatic renal cell carcinoma (RCC), and promote tumor regression in melanoma, but only a small percentage of patients respond [45, 46]. Preclinical data suggests that RT can promote memory T-cell formation through release of cytokines and upregulation of MHC-1, [47, 48] providing rationale for a phase 1 study that combined 1-3 fractions of RT (20 Gy per fraction) with high dose IL-2 for patients with metastatic RCC and melanoma. Response to treatment was correlated with a statistically significant increase in proliferating early activated effector memory T-cells [49]. Although IL-2 has shown promising potential in a subset of patients, there are significant toxicities associated with treatment, ranging from flu-like symptoms to vascular leak syndrome, which is the most frequent and severe complication of treatment [50, 51].
Currently, four phase 2 clinical trials are investigating the combination of high-dose IL-2 with SBRT in 1-3 fractions of 6-20 Gy each, enrolling patients with metastatic melanoma or RCC (Table 4). There are also phase 1 and 2 trials evaluating use of a recombinant fusion protein consisting of IL-2 with L19 human vascular targeting antibody (Darleukin, L19-IL2), which promotes lymphocyte and NK cell stimulation and immune-mediated tumor cell death, with less toxicity [52‐55]. This is delivered together with ablative doses of radiation in patients with oligometastatic or limited metastatic disease. Ongoing trials are summarized in Table 4.
Table 4
Active clinical trials combining radiation, miscellaneous
NCT Number | Phase | Title | Conditions | Interventions | RT Details | Enrollment | Sponsor/Collaborators |
|---|---|---|---|---|---|---|---|
Interleukin 2 | |||||||
NCT02086721 | Phase 1 | Phase I Clinical Study Combining L19-IL2 With SABR in Patients With Oligometastatic Solid Tumor | Solid Tumour | L19-IL-2 (recombinant protein with IL-2) | SBRT, 7.5-30 Gy in 1-8 fx | 18 | Maastricht Radiation Oncology |
NCT01416831 | Phase 2 | Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma. | Metastatic Melanoma | IL-2 | SBRT, 20 Gy × 1-2 fx | 44 | Providence Health & Services|Prometheus |
NCT01896271 | Phase 2 | High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer | Metastatic RCC, Melanoma | IL-2 | SBRT, 8-20 Gy in 1-3 fx | 26 | University of Texas Southwestern Medical Center|Prometheus |
NCT01884961 | Phase 2 | Radiotherapy as an Immunological Booster in Patients With Metastatic Melanoma or Renal Cell Carcinoma Treated With High-dose Interleukin-2 | Metastatic RCC, Melanoma | IL-2 | SBRT, 6-12 Gy × 3 fx | 19 | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori |
NCT02306954 | Phase 2 | Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer | Renal Cell Carcinoma | IL-2 | SBRT, 20 Gy × 2 fx | 84 | Providence Health & Services|Prometheus Laboratories |
NCT02735850 | Phase 2 | Combination of SABR and L19-IL2 in Patients With Stage IV Lung Cancer (ImmunoSABR) | Stage IV NSCLC, Limited Metastatic Disease | L19-IL-2 | SBRT | 141 | Maastricht Radiation Oncology |
Other Cytokines | |||||||
NCT01973322 | Phase 2 | Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumor Lysate or Homogenate Combined With Immunomodulating Radiotherapy and/or Preleukapheresis IFN-alfa in Patients With Metastatic Melanoma: a Randomized “Proof-of-principle” Phase II Study (ABSIDE) | Metastatic Melanoma | IFN-alfa | IMRT, 8-12 Gy in 3 fx | 24 | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori |
OX40 agonists | |||||||
NCT01862900 | Phase 1|Phase 2 | Phase I/II Study of Stereotactic Body Radiation Therapy to Metastatic Lesions in the Liver or Lung in Combination With Monoclonal Antibody to OX40 (MEDI6469) in Patients With Progressive Metastatic Breast Cancer After Systemic Therapy | Metastatic Breast Cancer | OX40 antibody (MEDI6469) | SBRT, 10-25 Gy in 1-2 fractions | 40 | Providence Health & Services |
TLR agonists | |||||||
NCT02180698 | Phase 1 | TLR4 Agonist GLA-SE and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma That Is Metastatic or Cannot Be Removed by Surgery | Metastatic Sarcoma | TLR-4 agonist (GLA-SE) | RT, 5-6 fx over 2 wks | 18 | Fred Hutchinson Cancer Research Center |
NCT02061449 | Phase 1 | Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma | Cutaneous T-cell Lymphoma | TLR3 agonist Poly-ICLC | RT, 3 fx | 24 | New York University School of Medicine|Ludwig Institute for Cancer Research |
NCT02254772 | Phase 1|Phase 2 | TLR9 Agonist SD-101, Ipilimumab, and Radiation Therapy in Treating Patients With Low-Grade Recurrent B-cell Lymphoma | Recurrent Lymphoma | TLR-9 agonist (SD-101), Ipilimumab | local RT | 27 | Ronald Levy|National Cancer Institute (NCI)|Stanford University |
NCT01421017 | Phase 1|Phase 2 | Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases | Metastatic Breast Cancer | TLR-7 agonist Imiquimod, Cyclophosphamide | RT, 6 Gy × 5 fx | 55 | New York University School of Medicine|National Cancer Institute (NCI) |
NCT01976585 | Phase 1|Phase 2 | In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy | Lymphoma | CDX-301, Poly-ICLC (TLR agonist) | Low dose RT | 30 | Joshua Brody|Icahn School of Medicine at Mount Sinai |
Cancer Vaccines | |||||||
NCT01436968 | Phase 3 | Phase 3 Study of ProstAtak™ Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer | Prostate cancer | AdV-tk vs placebo, valacyclovir +/- ADT | EBRT, 8 wks | 711 | Advantagene |
NCT02446093 | Phase 1|Phase 2 | Neoadjuvant GMCI Plus mFOLFIRINOX and Chemoradiation for Non-Metastatic Pancreatic Adenocarcinoma (PaTK02) | Pancreatic cancer | AdV-tk, mFOLFIRINOX, gemcitabine | EBRT | 44 | Ohio State University |
NCT01833208 | Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-T | Metastatic Prostate Cancer | Sipuleucel-T | High-dose 1 fx to bony metastasis | 15 | Roswell Park Cancer Institute|National Cancer Institute (NCI)|Dendreon | |
NCT01818986 | Phase 2 | Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC) | Metastatic Prostate Cancer | Sipuleucel-T | SBRT, metastatic site | 41 | University of Texas Southwestern Medical Center |
NCT02232230 | Phase 2 | A Multicenter Trial Enrolling Men With Advanced Prostate Cancer Who Are to Receive Combination Radiation and Sipuleucel-T | Metastatic Prostate Cancer | Sipuleucel-T | RT, metastatic site | 100 | 21st Century Oncology|Dendreon |
Interferon alpha (IFN-α)
Interferon alpha (IFN-α) generated interest after preliminary studies demonstrated a survival advantage in pancreatic cancer patients, resulting in a phase 2 trial (NCT00059826) combining IFN-α with adjuvant chemoRT in resected pancreatic cancer patients [56]. Although the observed median survival of 25.4 months was promising compared to historical standards, the regimen had considerable high-grade toxicity, resulting in early closure of the study.
Results of a phase 2 trial (NCT01276730) randomizing locally advanced cervical cancer patients to RT with cisplatin versus IFN-α plus retinoic acid were recently reported [57]. Primary endpoint was overall survival at 3 years. Unfortunately, there was no survival advantage demonstrable with the addition of IFN-α, though toxicity was acceptable. There is currently one actively recruiting phase 2 study (ABSIDE, NCT01973322), randomizing patients with metastatic melanoma to four different arms, with one of the arms exploring use of IFNα with a dendritic cell vaccine and RT, 8-12 Gy in 3 fractions; results are pending.
Tumor necrosis factor alpha (TNF-α)
TNF-α is a cytokine produced by activated macrophages and other immune cells, inducing diverse effects such as immune cell activation and tumor cell apoptosis. Initial studies incorporating TNF-α with radiation resulted in unacceptably high rates of toxicity [58]. TNFerade is an adenovector-based gene therapy agent, wich allows radiation-induced translation of TNF- α via a radiation-inducible promoter. Studies using TNFerade intratumoral injection with RT showed acceptable toxicity, [59] providing stimulus for subsequent phase 1 and 2 studies exploring the combination of TNFerade with RT in different primary cancers. Phase 1 studies suggested improved overall and progression-free survival in esophageal cancer, head and neck cancer and other solid tumors [60‐64]. This resulted in a phase 3 randomized trial for locally advanced pancreatic cancer patients, treated with standard of care (SOC) chemoRT, vs SOC + TNFerade [65]. Levels of grade 3-4 toxicity were similar between the two arms, but there was no improvement in median survival with the addition of TNFerade. This dampened enthusiasm for this novel approach, and there are currently no open studies exploring TNFerade with RT.
Costimulatory antibodies
OX40 agonists
OX40 (CD134) is a member of the TNF receptor superfamily, expressed on activated CD4+ and CD8+ T-cells, and induced on activated regulatory T-cells, NK cells and neutrophils [66]. Stimulation of OX40 results in proliferation of CD4+, CD8+ T cells, cytokine production and memory T cell promotion, and suppression of regulatory T-cells, making it an attractive target for combination strategies with RT. Preclinical studies combining single fraction RT (20 Gy) with OX40 activation have demonstrated increased survival and disease regression, correlating with increased tumor infiltration by CD8+ T-cells [67, 68]. The ability of OX40 to enhance T-cell memory and proliferation, while suppressing regulatory T-cell function in preclinical models resulted in enthusiasm for the combination of OX40 agonists with RT, surgery or systemic agents [69]. A phase 1 clinical trial testing an antibody agonist of OX40 with cyclophosphamide and single fraction RT (8 Gy) in metastatic prostate cancer patients is currently ongoing, though no longer recruiting (NCT01642290). Results of the immunological analysis were reported in abstract form in 2013, [70] and showed increased proliferation of CD4+, CD8+ and NK cells in peripheral blood lymphocytes, along with increased interferon gamma and IL-2. There was no change in proliferation of regulatory T-cells. There is also a phase 1/2 trial combining monoclonal antibody agonist of OX40 (MEDI6469) with SBRT in 1-2 fractions of 10-25 Gy each in breast cancer patients with lung or liver metastases (NCT01862900).
Dendritic cells (DCs)
The first category of DC-based immunotherapy entails intratumoral injection of autologous DCs to promote the cross priming of T cells to tumor antigens after RT, and increase tumor infiltration of CD8+ T-cells [71]. This approach has been utilized in a phase 1 trial in patients with hepatocellular carcinoma who were treated with single fraction RT (8 Gy) and injected with autologous DCs two days later. Out of 14 patients, 50 % demonstrated a minor to partial clinical response [72]. Another phase I study (NCT00365872) evaluated intratumoral DC injection with neoadjuvant RT to 50 Gy in 25 fractions in soft tissue sarcoma, with primary endpoint to evaluate immunologic response [73]. Ten of 18 patients (56 %) demonstrated a tumor specific immune response, though any correlation with outcome could not be established due to small numbers. The same institution subsequently initiated a phase 2 trial combining intratumoral DC injection and RT to 50 Gy (NCT01347034), which is active but no longer recruiting. There is also a completed phase 1/2 trial with results pending, combining intratumoral DC injection with SBRT and gemcitabine. Currently, there are no actively recruiting studies exploring this approach.
Toll-like receptor (TLR) agonists
Irradiation activates DCs in part via the release of TLR agonists by dying cells [74]. TLR-targeted therapy can enhance the effect of RT by improving antigen presentation by DCs. A variety of TLR agonists have been utilized in combination with RT in the preclinical and clinical setting, including IMM-101, a suspension of Mycobacterium that acts as a TLR-2 agonist; GLA-SE (glucopyranosyl lipid A), a TLR-4 agonist; poly-ICLC, which binds to TLR-3; Z-100, (ZERIA Pharmaceuticals), an extract obtained from Mycobacterium tuberculosis strain Aoyama B, which activates the innate immune system and modulates macrophage activity through an unclear mechanism; CpG (cytosine phosphate guanine), which binds to TLR9, [75] and imiquimod, which activates TLR-7 [76, 77]. A phase 3 trial for locally advanced cervical cancer randomized patients to standard of care chemoRT versus standard of care plus Z-100. There was a trend towards improved overall survival with the addition of a TLR agonist [78]. A phase 1 trial in anaplastic glioma patients administered poly-ICLC as an intramuscular injection with RT to 60 Gy total in daily 2 Gy fractions, and found a favorable overall survival rate at 1 year of 69 % [79].
CpG oligodeoxynucleotides have been shown to stimulate the anti-tumor immune response via TLR-9 mediated DC activation. Direct intratumoral injection of CpG has been studied with low-dose RT (2 Gy x 2) in a phase 1/2 study of mycosis fungoides patients, with a 50 % response rate outside of the treated site (NCT00226993) [80]. A similarly designed phase I/II study combined low dose RT (2 Gy x 2) with intratumoral injection of CpG in recurrent low-grade lymphoma patients, with promising response rate of 27 % in non-irradiated tumors (NCT00185965) [81]. Overall, this approach was well tolerated, with no treatment limiting adverse events. All patients demonstrated a tumor-specific immune response within 4 weeks. The combination approach of a second-generation TLR9 agonist (SD-101) with ipilimumab and low-dose RT is under study for low-grade lymphoma as part of a phase 1/2 dose-escalation trial (NCT01745354). At present, there are a handful active phase 1/2 studies exploring use of TLR agonists with RT in lymphoma, metastatic breast cancer and metastatic soft tissue sarcoma (Table 4).
Cancer vaccines
Another approach for enhancing anti-tumor immunity is vaccination through presentation of tumor antigens on recombinant viral vectors. The combination of tumor vaccines with RT has shown promise in preclinical settings and small phase 1/2 studies. Use of a poxviral-based vaccine to target PSA was combined with definitive RT in localized prostate cancer patients [82]. Vaccination was administered with GM-CSF and IL-2 as immunostimulatory adjuvants. Out of the 17 patients who completed the course of vaccinations, 13 exhibited at least 3-fold increase in PSA-specific T-cells, compared to no detectable increase with RT alone. There was also evidence of T-cell responses to prostate-associated antigens not present in the vaccine, suggestive of antigenic cascade or epitope spreading possibly induced by RT [83]. A subsequent phase 2 trial in 33 men with intermediate- to high-risk prostate cancer demonstrated a detectable PSA-specific T-cell response with vaccination [84]. Results of a phase 1 trial in pancreatic cancer (NCT00638612) were recently reported, [85] demonstrating the feasibility and safety of a combination approach incorporating recombinant viral vector vaccines with chemoRT. Similar results have been shown for a parallel approach in malignant gliomas [86]. Currently, there is an ongoing phase 3 trial randomizing men with localized prostate cancer to an adenoviral vector based PSA-vaccine (ProstAtak) with definitive RT vs placebo (NCT 01436968), and a phase 1/2 study exploring use of a similar strategy with chemoRT in locally advanced pancreatic cancer (NCT02446093).
There are multiple cancer vaccines under development or recent approval, and studies combining novel vaccines with RT to promote synergistic anti-tumor immunity are underway. Sipuleucel-T (Provenge) is a type of cancer vaccine consisting of autologous antigen-presenting cells, activated ex vivo and loaded with PAP (prostatic acid phosphatase) antigen, which is expressed by the majority of prostate cancer cells, and GM-CSF to promote DC maturation. Sipuleucel-T has been approved for use in metastatic, castrate-resistant prostate cancer based on phase 3 clinical trials demonstrating improved overall survival [87]. There are currently 3 active clinical trials assessing use of radiation as an immunogenic adjuvant in combination with sipuleucel-T (Table 4).
Clinical considerations for trial evaluation
The number of clinical trials exploring use of RT with immunotherapy is rapidly increasing. It is evident that RT can expose tumor antigens to the immune system, but the optimal partnering with immunotherapies to maximize this effect remains unclear. As we move forward, there are several questions that remain unanswered, warranting discussion of relevant considerations in appropriate trial design and evaluation.
RT Parameters
At present, a wide range of dose and fractionation schedules are being utilized in clinical studies, and the optimal regimen to elicit an immune response remains unknown. Also unclear is whether a lower RT dose is superior to an ablative dose in this context. The appropriate selection of RT dose and fractionation is likely to be a critical determinant in successful generation of an antitumor immune response. Preclinical studies in breast and colon cancer models suggest that 3 fractions of 8 Gy, and 5 fractions of 6 Gy, remain superior to a single ablative dose of 20 Gy in combination with CTLA4 blockade to generate an abscopal response [15]. It is notable, therefore, that clinical reports of abscopal effects after CTLA4 blockade and RT have utilized similar regimens of 3 to 5 fractions, supporting these findings [26, 30]. While a fractionated approach seems superior to a single dose strategy, it remains to be determined whether ablative doses of RT could have resulted in a similar or enhanced response. Furthermore, since these studies were performed with CTLA4 blockade, further investigations need to be performed with other immune checkpoint inhibitors to determine whether similar differences will be demonstrable. Results of thoughtfully designed prospective studies will help address this question.
The size of the treatment field also influences the partnership between radiation and induction of an antitumor immune response. Circulating lymphocytes are highly sensitive to RT, with a D90 of 0.5 Gy [88]. Larger treatment fields expose a greater volume of circulating lymphocytes to RT, and also impact proliferating T-cells and potential T-cell priming in draining lymphatic regions. Even with smaller, more conformal RT fields, protracted RT regimens expose circulating lymphocytes to lymphotoxic doses, which may exhaust T-cells [89]. Strategies to reduce RT-induced lymphopenia include hypo-fractionation, reduction in treatment field size with highly conformal techniques such as SBRT/SRS and shortening of beam-on treatment times.
Another consideration when partnering RT with immunotherapy is the target site. A phase 3 trial combining a single fraction of RT to 8 Gy with CTLA-4 blockade failed to demonstrate improved overall survival, but RT was delivered on a single dose and directed towards an osseous metastasis [35]. Though abscopal responses have been seen with RT given to a bone metastasis, [90] it is notable that most published reports demonstrating abscopal responses have mainly resulted from RT directed to visceral metastases, with multiple fractions.
Sequencing of therapies
The optimal sequencing of RT with immunotherapy likely depends on the type of treatment used and mode of action. All reported cases of abscopal response in CTLA-4 blockade have occurred in patients who received RT concurrent with, or immediately after, therapy [15, 26, 30]. Preclinical models demonstrate that administration of RT first, followed by delayed CTLA-4 blockade, results in inferior outcomes, [15] supporting use of concurrent therapy. The majority of currently ongoing trials utilize concurrent immune checkpoint blockade with RT. An intriguing question is whether addition of other immunotherapies in a staged or concomitant fashion can improve outcomes by promoting likelihood of immunization against the tumor, and avoid T-cell exhaustion. Such an approach can incorporate RT as one of the steps in a thoughtfully designed trial.
Trial endpoint selection
It remains to be determined whether conventional trial endpoints such as progression-free survival, local control and disease-free survival are relevant measures of response to immunotherapy. As an example, patients randomized to sipuleucel-T, an immunotherapeutic vaccine, showed no objective response or improvement in time to disease progression, yet achieved a statistically significant 4.1 month improvement in overall survival [87]. Traditional RECIST criteria fail to account for transient increases in tumor size, which has been known to occur after immunotherapy, and can occur prior to a clinical response. Furthermore, the combination of local RT and immunotherapy can impact distant, or new lesions over the targeted lesion. In an effort to overcome these limitations, and account for changes in total tumor burden throughout the body, immune-related response criteria have been proposed [91, 92]. Improved methods of monitoring response after immunotherapy and RT are being developed, and clarity on relevant endpoint selection will be obtained as data emerges from ongoing studies. At present, overall survival, safety/toxicity and quality of life impact appear superior to traditional endpoints of disease/progression free survival and local control.
Patient selection
Selection of appropriate patients for trial enrollment is critical, factors such as degree of myelosuppression, overall tumor burden, neutrophil to lymphocyte ratio and prior exposure to RT and chemotherapy should be taken into consideration [43]. Depletion of immune cells decrease likelihood of immune response; thus patients with decreased lymphocyte counts due to cytotoxic chemotherapy and marrow infiltration by tumor are likely to be poor responders to treatment. Similarly, the use of larger fields during classical prolonged fractionated regimens of 30-40 fractions inevitably will reduce the availability of effector and memory cells [72]. In addition, tumor burden at the time of intervention with immunotherapy and radiation may influence outcome since patients with a significant metastatic burden did not benefit from a combined approach of CTLA-4 blockade and RT, whereas limited disease burden correlated with improved survival [35].
Conclusion
The combination of RT with immunotherapy has exciting potential to transform cancer treatment by harnessing the immune system in a synergistic approach. While evidence in support of this combination continues to accumulate, additional data is warranted in order to determine safety and efficacy, and results of ongoing clinical trials will help address this need. In addition to this, well-designed, prospective trials will help determine the optimal dose, technique and sequencing of RT with immunotherapies. Development of biomarkers to predict treatment response to immunotherapies will help identify patients most likely to benefit from different treatments. An exciting new field of research is developing, and results of ongoing clinical trials are eagerly awaited.
Abbreviations
GY, gray; RT, radiation therapy.
Acknowledgements
Drs. Formenti and Demaria receive salary supported from the Breast Cancer Research foundation, NIH/NCI, The Chemotherapy Foundation and the Department of Defense Breast Cancer Research Program.
Advertisement
Funding
No funding.
Availability of supporting data
N/A.
Authors’ contributions
Dr. JK has designed with Dr. SF the structure of the review and has provided a first draft of the manuscript. Dr. SF and SD have reviewed, corrected and edited the content of the manuscript. Dr. SF has performed the final review and editing and has submitted the manuscript, as corresponding author. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Advertisement
Consent for publication
N/A.
Ethics approval and consent to participate
N/A.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.